Tern appoints Rob Stevens as adviser on shareholder relations

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that the Board of Tern has appointed Robert (Rob) Stevens as an adviser to the Company on shareholder relations.

Mr Stevens, a private shareholder in the Company, brings experience of the UK small-cap investment community and will provide the Board with strategic advice and guidance, in conjunction with the Company’s other advisers, on investor communications and shareholder sentiment, to allow the Company to remain closely attuned to market views as it pursues its long-term value creation strategy.

The Board will continue to evaluate the appropriateness of appointing additional advisers in due course, as part of its ongoing commitment to enhancing shareholder engagement and value creation.

Conditional Grant of Options

Mr Stevens has conditionally been granted 1,000,000 options over ordinary shares of 0.02p each in the Company.

The grant and any exercise of the Conditional Options will be conditional on the Company obtaining the requisite authorities to satisfy the issue and allotment of any new Ordinary Shares resulting from the future potential exercise of the Conditional Options, which will involve the passing of a resolution at a future general meeting of shareholders.

Subject to the satisfaction of the Conditions, the Conditional Options will vest in equal monthly amounts over three years from the date of the satisfaction of the Conditions, and will be exercisable for a period of 10 years from the date of vesting at a price of 1.70p per Ordinary Share, being approximately double the mid-market closing price of the Ordinary Shares on 29 August 2025, the last practical date prior to this announcement.

Following the satisfaction of the Conditions, the total number of options outstanding over Ordinary Shares in Tern Plc will be 11,500,000.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines uses AI to turn medical congress discussions into pharma insights

Talking Medicines uses AI to analyse healthcare professional conversations at medical congresses, turning discussions into structured insights that help...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Search